Adcentrx Therapeutics has received IND approval from China's NMPA for ADRX-0706, a new Nectin-4 antibody-drug conjugate designed to treat advanced solid tumors.

Modalis Therapeutics Announces Promising Results for MDL-101, a Novel Epigenome Editing Treatment for LAMA2 Congenital Muscular Dystrophy (LAMA2-CMD).

Inmagene Announces Encouraging Early Outcomes of Phase 2a Study on IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody, Prolonged Duration, Aimed at Treating Atopic Dermatitis.

Boehringer Ingelheim has revealed encouraging results from its HORNBILL Phase I/IIa trial for BI 764524.

BioAtla Receives FDA Approval to Begin Trials of BA3361, a Conditionally Active Biologic (CAB) Targeting Nectin-4 in Various Cancers.

Mediar Initiates Clinical Stage for Its Unique Fibrosis Collection with Initial Group Treatment in Phase 1 Study of MTX-463, and Forms a Clinical Advisory Committee.

GIBF commits $10 million in funding to Nectin Therapeutics for the development of innovative first-in-class immunotherapies and antibody-drug conjugates.

Edgewise Therapeutics has administered the initial dose to a participant in the Phase 2 CIRRUS-HCM study, evaluating EDG-7500 in patients with Obstructive Hypertrophic Cardiomyopathy (HCM).

Fate Therapeutics Reveals FT522 Early-Stage Data on Autoimmune Disorders in a New Abstract at the ASGCT Annual Conference.

HanAll Biopharma Launches Phase III Double-Blind, Placebo-Controlled VELOS-4 Study to Assess Tanfanercept in Treating Dry Eye Syndrome.

TAR-200 treatment alone achieves over 80% total remission in high-risk patients with non-muscle-invasive bladder cancer.

Guangzhou Bio-gene Technologies has launched the first phase of clinical trials for its CAR-T cell therapy BG1805, which targets CLL-1.